{"id":54252,"date":"2022-01-22T17:18:52","date_gmt":"2022-01-22T16:18:52","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/combined-therapy-of-ocular-surface-disease-with-plasma-rich-in-growth-factors-and-scleral-contact-lenses\/"},"modified":"2026-09-30T17:56:24","modified_gmt":"2026-09-30T16:56:24","slug":"combined-therapy-of-ocular-surface-disease-with-plasma-rich-in-growth-factors-and-scleral-contact-lenses","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/fr\/combined-therapy-of-ocular-surface-disease-with-plasma-rich-in-growth-factors-and-scleral-contact-lenses\/","title":{"rendered":"Combined therapy of ocular surface disease with plasma rich in growth factors and scleral contact lenses"},"content":{"rendered":"

[vc_row content_text_aligment=”left” row_background_lines=”no”][vc_column][vc_column_text]<\/p>\n

Abstract<\/h3>\n
\n
\n

Purpose: <\/strong>To review safety and efficacy of combined plasma rich in growth factors (PRGF) eye drops and scleral contact lens (SCL) therapy in patients with ocular surface disease.<\/p>\n

Methods:\u00a0<\/strong>Patients with ocular surface disease of various etiologies were screened for at least 3 months of concurrent treatment with PRGF and SCL. Retrospective pre- and post-treatment measurements were collected, including patient satisfaction, severity and frequency of dry eye symptoms measured by a modified Symptom Assessment in Dry Eye (SANDE) questionnaire, visual acuity, and number of concurrent treatments.<\/p>\n

Results: <\/strong>26 patients with ocular surface disease were included in the study with 20 patients answering the questionnaire (77% response rate). There were no adverse events reported. Most patients thought the combined therapy was better than previous treatments and would recommend to others (80%, 90% respectively). SANDE scores significantly decreased after use of concurrent therapy. There was a small but significant decrease in the number of other concurrent treatments. Visual acuity was unchanged.<\/p>\n

Conclusions:\u00a0<\/strong>This retrospective cohort study found PRGF used in combination with SCL is safe and significantly decreases symptoms in patients with recalcitrant ocular surface disease.<\/p>\n<\/div>\n

Keywords:\u00a0<\/strong>Dry eye; Ocular surface disease; Plasma rich in growth factors; Scleral contact lenses.<\/p>\n<\/div>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row][vc_column]\n Acc\u00e9der \u00e0 l'article complet<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Ocul Surf. 2022 Jan;23:162-168.<\/strong>
\nTo review safety and efficacy of combined plasma rich in growth factors (PRGF) eye drops and scleral contact lens (SCL) therapy in patients with ocular surface disease.<\/p>\n","protected":false},"author":2002,"featured_media":54135,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[155],"tags":[],"class_list":["post-54252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medecine-regenerative"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/54252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/comments?post=54252"}],"version-history":[{"count":1,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/54252\/revisions"}],"predecessor-version":[{"id":54253,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/54252\/revisions\/54253"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/media\/54135"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/media?parent=54252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/categories?post=54252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/tags?post=54252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}